

AASLD
The Liver
Meeting®



INDUSTRY PROGRAMMING GUIDE

SATELLITE SYMPOSIA

Page 5

TLM THEATERS

Page 21



NOVEMBER 7-11, 2025 • Washington, DC
www.aasld.org/the-liver-meeting



COMPREHENSIVE CHB TESTING: QUANTITATIVE & QUALITATIVE HBsAg AND BEYOND

Chronic Hepatitis B (CHB)

Learn more about **comprehensive biomarker testing**
at our interactive presentation.

Sunday, November 9, 2025
12:30 PM-1:30 PM

Lunch Provided

Visit GSK BOOTH #509



Scan to learn more

[KnowHepBTesting.com](https://www.knowhepbtesting.com)

Trademarks are owned by or licensed to the GSK group of companies.

©2025 GSK or licensor.
NPUS-HBUBNNR250005 September 2025
Produced in USA.

GSK

Visit the

EXHIBITS Hall D/E

Saturday, Nov. 8

6:00 – 7:30 PM

Opening Reception in Exhibit Hall

Sunday, Nov. 9

9:30 AM – 5:00 PM

Monday, Nov. 10

9:30 AM – 5:00 PM



Scan the QR code
to view exhibitors
and Exhibit Hall map



Raising the Bar: **Innovations in PBC Care**



Saturday, November 8, 2025
12:30 PM - 2:00 PM ET

Walter E. Washington Convention Center
801 Allen Y. Lew Place NW
Washington, DC 20001

Room: 152

FACULTY:

Christopher L. Bowlus, MD
Aparna Goel, MD
Aliya Gulamhusein, MD,
MPH, FRCPC



**Scan to
register**

Beyond the Status Quo: **Exploring the Future Impact of HBV Innovations**

Monday, November 10, 2025
12:30 PM - 2:00 PM ET

Walter E. Washington Convention Center
801 Allen Y. Lew Place NW
Washington, DC 20001

Room: 152

FACULTY:

Jordan J. Feld, MD, MPH
Mark Sulkowski, MD, FAASLD
Grace L. H. Wong, MD, MBChB (Hons), FRCPC
(Lond, Edin), FHKCP, FHKAM (Medicine)



**Scan to
register**

SATELLITE SYMPOSIA

Listings current as of October 10, 2025. Please refer to mobile app for updates.

Friday, Nov. 7

Expert Perspectives on the Diagnosis and Proactive Management of Metabolic Dysfunction-Associated Steatohepatitis

12:30 - 2:00 PM

Convention Center, Room 147

SUPPORTED BY: Novo Nordisk

ORGANIZED BY: Med Learning Group

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Naim Alkhouri, MD, FAASLD, DABOM; Sonal Kumar, MD, MPH

This interactive symposium will enhance knowledge of metabolic dysfunction-associated steatohepatitis (MASH) diagnosis, risk stratification, and treatment. Expert-led sessions will review noninvasive diagnostic tools, guideline-driven staging, lifestyle interventions, and emerging therapies. Case-based discussions will engage learners in applying concepts to clinical scenarios and addressing real-world challenges in the diagnosis and proactive management of MASH.

LEARNING OBJECTIVES

- Implement AASLD guideline recommendations to enable early MASH diagnosis, including MASH screening for at-risk individuals and the use of non-invasive diagnostic techniques, such as biomarker- and imaging-based testing
- Incorporate AASLD guideline recommendations for the medical management of MASH, including lifestyle modification and pharmacologic management recommendations, into clinical practice
- Analyze the efficacy and safety data from MASH clinical trials evaluating treatment with resmetirom or GLP-1 RAs for patients with MASH to inform the development of patient-centric, evidence-based treatment plans

For more information and to register, visit: www.medlearninggroup.com/cme-programming/mash-sympo/



See what
makes
LIVDELZI
different

Actor portrayals.

Stop by **booth #700**
and explore **LIVDELZI**.



LIVDELZI, the LIVDELZI Logo, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies.

© 2025 Gilead Sciences, Inc. All rights reserved. US-LIVP-0303 08/25

The Capitol Challenge: Mastering PBC Care

12:30 – 2:00 PM

Convention Center, Room 150

SUPPORTED BY: Intercept

ORGANIZED BY: Medscape Education

CME: Maximum of 1.25 AMA PRA Category 1 Credits

PRESENTERS: Emma Culver, MBChB, Dphil, FRCP; Steven L. Flamm, MD, FAASLD, FACP; Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FADG

Join us for a symposium on primary biliary cholangitis (PBC) designed to encourage the exchange of ideas between leaders in the field and attendees.

LEARNING OBJECTIVES

Upon completion of this activity, participants will have greater competence related to:

- Monitoring PBC disease activity and progression in practice
- Identifying patients with PBC who require second-line therapy
- Selecting evidence-based second-line therapies for patients with PBC
- Demonstrating greater confidence in their ability to tailor treatments for patients with PBC

For more information and to register, visit: <https://www.medscape.org/sympo/pbc-challenge-25>

The Steatotic Liver Showdown: A Game Show on MASLD/MASH

7:30 – 9:30 PM

Marriott Marquis, Marquis Ballroom Salon 6

SUPPORTED BY: Boehringer Ingelheim Pharmaceuticals, Inc.

ORGANIZED BY: Medscape Education

CME: Maximum of 1.25 AMA PRA Category 1 Credits

PRESENTERS: Meena Bansal, MD, FAASLD; Sonal Kumar, MD, MPH; Mazen Nouredin, MD, MHSc

Join us for a gameshow-style symposium on metabolic dysfunction-associated steatohepatitis (MASH) designed to encourage the exchange of ideas between leaders in the field and attendees.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

- Recognize the relationship between obesity and MASH
- Compare outcomes for incretin-based therapies in the treatment of MASH
- Select noninvasive risk stratification modalities to determine treatment strategies for patients with MASH

For more information and to register, visit: www.medscape.org/sympo/liver-showdown

Stay Connected



Follow AASLD on social media and use the official hashtag #TLM25 to connect with fellow attendees online.

Satellite Symposia

Saturday, Nov. 8

Saturday, Nov. 8

A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration

12:30 - 2:00 PM

Convention Center, Room 151

SUPPORTED BY: Madrigal Pharmaceuticals

ORGANIZED BY: AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC

CME: Maximum of 1.25 AMA PRA Category 1 Credits

PRESENTERS: Naim Alkhouri, MD, FAASLD; Meena B. Bansal, MD, FAASLD; Rohit Loomba, MD, MHSc

Join our experts as they discuss practical aspects of integrating liver-directed therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Listen as they discuss real-world successes and challenges with using THR-B agonists and GLP-1RAs. Catch up on the latest data on noninvasive testing and other treatments in late-stage development.

LEARNING OBJECTIVES

Upon successful completion of this activity, participants should be better able to:

- Describe the mechanistic and clinical rationale for THR-b agonists as a means of treating MASLD/MASH
- Evaluate the evidence on THR-b agonists, and other disease-specific therapy classes, considering efficacy, safety/tolerability, and PROs
- Identify best practices for facilitating and documenting an accurate, non-invasive, and timely diagnosis of MASLD/MASH to support access to disease-specific therapy
- Develop guideline-aligned management paradigms for MASLD/MASH that incorporate pharmacotherapy tailored to individual clinical scenarios

For more information and to register, visit: www.eventbrite.com/e/1564244961789?aff=oddtcreator



Download the mobile app
for updates, and add these
events to your schedule.



Connecting the Clues: Lung and Liver Considerations in Diagnosing Alpha-1 Antitrypsin Deficiency

12:30 - 2:00 PM

Convention Center, Room 150

SUPPORTED BY: Takeda

ORGANIZED BY: Medscape Education

CME: Maximum of 1.0 AMA PRA Category 1 Credits

PRESENTERS: Aleksander Krag, MD, PhD, MBA; James K. Stoller, MD, MS; Pavel Strnad, MD

Join us for a symposium on alpha-1 antitrypsin deficiency (AATD) designed to encourage the exchange of ideas between leaders in the field and attendees.

LEARNING OBJECTIVES

Upon completion of this activity, participants will have increased knowledge regarding:

- Multi-organ manifestations of AATD
- Consequences of a delayed AATD diagnosis
- Emerging treatment approaches for AATD-associated liver disease
- Identification of patients at risk of AATD-associated liver disease
- Addressing barriers related to the delayed diagnosis of AATD-associated liver disease

For more information and to register, visit: <https://www.medscape.org/sympo/aatd2025>

Biliary Atresia:

How do we better understand pathways and disease progression?

Join our expert-led symposium on
Monday 10th November, 12:30–13:00, ET
TLM Theater 1, Exhibit Hall D

Explore current approaches to the management of Biliary Atresia, opportunities for further optimization of care and patient outcomes, and better understand prognostic biomarkers and the pathophysiology behind disease progression



Ronald J Sokol,
MD, FAASLD
University of Colorado
School of Medicine



Binita Kamath,
MBBChir, FAASLD
Children's Hospital
of Philadelphia

We look forward to seeing you there!



©2025 Ipsen
Biopharmaceuticals, Inc.
All rights reserved.

This is an educational event sponsored by Ipsen Biopharma. This is not a Continuing Medical Education (CME) event. Intended for healthcare professionals only.

ALLSC-ALL-007018
September 2025

Satellite Symposia

Saturday, Nov. 8

Raising the Bar: Innovations in PBC Care

12:30 – 2:00 PM

Convention Center, Room 152

SUPPORTED BY: Gilead Sciences, Inc.

ORGANIZED BY: Clinical Care Options, LLC

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Christopher L. Bowlus, MD; Aparna Goel, MD; Aliya Gulamhusein, MD, MPH, FRCPC

This interactive symposium will feature expert perspectives on advancing the standard of care for individuals living with primary biliary cholangitis (PBC). Discussion will focus on strategies aimed at achieving normalization of biochemical markers, alleviating symptom burden, and exploring the potential role of new and emerging therapies in improving patient outcomes.

LEARNING OBJECTIVES

- Develop treatment goals for PBC that include evidence-based biochemical targets and improvement in symptoms and quality of life
- Outline the role of new PBC therapies in achieving biochemical targets and symptom management
- Design comprehensive treatment plans for patients with PBC

For more information and to register, visit: www.clinicaloptions.com/2025PBCraisingthebarDC

YOUR NEXT CHAPTER STARTS WITH US



Elevate your career within Northwell's world-class Center for Liver Disease and Transplantation. We are actively seeking dynamic physicians to join our thriving Division of Hepatology across our expansive New York footprint, including Suffolk, Nassau, Manhattan, and Westchester. These academic positions offer a unique opportunity to provide comprehensive patient care in liver disease and transplantation – from diagnosis to pre- and post-transplant management – while actively shaping the next generation of medical professionals through teaching and research. Join an innovative, collaborative team at the Northwell Transplant Institute, renowned for delivering exceptional outcomes and access to care within two top-ranked hospitals and an expansive network of 40+ locations. Our physicians enjoy many benefits, including:

- Competitive salaries
- Comprehensive benefits package
- Paid Time Off plus paid conference/CME time
- Academic appointment at Hofstra/Northwell School of Medicine commensurate with experience
- Advanced education opportunities
- College Tuition reimbursement for dependent children
- Collaborative research opportunities present at the Feinstein Institute for Medical Research and Cold Spring Harbor Laboratories

WE ARE HIRING BE/BC ACADEMIC TRANSPLANT HEPATOLOGISTS

READY TO GROW YOUR CAREER?

To learn more, please email us:
OPR@northwell.edu



Northwell™

Toward Functional Cure in Chronic HBV: Monitoring, Serological Markers, and Evolving Therapy

12:30 - 2:00 PM

Convention Center, Room 147

SUPPORTED BY: GSK

ORGANIZED BY: PVI, PeerView Institute for Medical Education

CME: Maximum of 1.0 AMA PRA Category 1 Credits

PRESENTERS: Tatyana Kushner, MD, MSCE; Paul Kwo, MD, AGAF, FACG, FAASLD

Join PeerView and leading experts for an engaging symposium on advancing functional cure in chronic hepatitis B. Gain insights on how qHBsAg testing sharpens decision-making, explore evolving antiviral therapies, and apply guideline-based strategies to monitor treatment success and prevent complications. Elevate your HBV practice and improve outcomes for your patients.

LEARNING OBJECTIVES

- Learn how qHBsAg testing can guide clinical decisions and improve care in chronic HBV
- Hear how to use evidence-based care to help patients with CHB reach functional cure and avoid serious complications
- Explore guideline-based strategies to track CHB progression, complications, and treatment success

For more information and to register, visit: [PeerView.com/Washington-HepB-Live](https://www.peerview.com/washington-hepb-live)

JOIN AASLD: STAY INFORMED, CONNECTED & AHEAD IN HEPATOLOGY

- Keep current with HEPATOLOGY and Liver Transplantation.
- Access expert-led courses and content through LiverLearning®.
- Utilize evidence-based recommendations for patient care.
- Benefit from research funding, mentorship, and job search resources.
- Engage with top professionals through Special Interest Groups.



**JOIN
AASLD
TODAY!**

More Than Fat in the Liver: The Metabolic Burden of Excess Adiposity

Boehringer Ingelheim invites you to join our expert faculty for this product theater.

 **Monday,
November 10, 2025**

 **3:30 PM –
4:15 PM ET**

 **TLM Theater #2,
Exhibit Hall D/E**

Meet the Speakers!



Nadege Gunn, MD, CPI, DABOM, FAASLD

Medical Director & Senior Scientific Advisor, Velocity Clinical Research
Community Hepatology Clinic Director, Coryell Health
Adjunct Assistant Professor, Texas A&M College of Medicine
Waco, Texas



Angela Fitch, MD, FACP, FOMA, Dipl. ABOM

Co-Founder, Chief Medical Officer, Metabolic Health & Primary Care Physician, knownwell
Past President of the Obesity Medicine Association
Needham, Massachusetts

Program Description

Explore the metabolic connections between obesity, MASLD/ MASH, and cardiometabolic diseases, and how incorporating obesity care in hepatology practice can improve multiple health outcomes. Join expert clinicians for an in-depth discussion on the vital role of hepatology in obesity care and the importance of collaborative care.

Let's connect! Find us at Booth #757.



Scan the QR code or visit
seeobesitythinkliver.com to learn more!

MASH, metabolic dysfunction–associated steatohepatitis; MASLD, metabolic dysfunction–associated steatotic liver disease.

This event does not qualify for continuing medical education (CME) credit.

This information is intended for US healthcare professionals only.

Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT 06877



MASLD and Cardiometabolic Syndrome: The Dream MDT Team!

7:30 – 9:30 PM

Marriott Marquis, Marquis Ballroom Salon 6

SUPPORTED BY: Perspectum Ltd

ORGANIZED BY: HealthProMatch

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Lee Kaplan MD PhD; Kathy Magliato, MD, MBA, FACS; Jacqueline O'Leary, MD, MPH; Niharika Samala, MD; Jose Vargas, MD

Metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, cardiometabolic syndrome, and type 2 diabetes mellitus (T2DM) are all overlapping yet distinct diseases. Follow a patient in real time from primary to tertiary care. Challenge the experts in hepatology, cardiology, and obesity medicine as they debate the latest research and missed opportunities along the patient's journey: Juggle polypharmacy, lifestyle interventions, biomarkers, multimodal imaging. Interactive Evening Symposium. Dinner and refreshments provided.

LEARNING OBJECTIVES

- Evaluate current evidence-base and accessibility for non-invasive tests (NITs) in the screening, diagnosis, monitoring and prognostication of patients at risk of or living with cardiometabolic syndrome and/or MASLD
- Compare and contrast beneficial and harmful effects and interactions between emerging pharmacotherapies in MASLD and cardiometabolic syndrome in order to tailor to patients needs
- Design MDT pathways and define the role of the hepatology practitioner when managing patients with multi-organ involvement at risk of or living with cardiometabolic syndrome and MASLD.

For more information and to register, visit: healthpromatch.com/courseRegistration/?courseId=6



Claiming CME for The Liver Meeting 2025

CME credit claiming for The Liver Meeting 2025 will open on Friday, Nov. 7, 2025. For information on how to claim credits, scan the QR code.

ADVANCES in MASH: Data From a Phase 3 Study^a

Novo Nordisk invites you to join our expert faculty and your colleagues for this sponsored educational program.



Faculty

**Manal F. Abdelmalek, MD, MPH, FACP,
FACG, FAASLD**

Professor of Medicine

Director, MASLD Clinical Research Program

Mayo Clinic

Rochester, MN



**Sunday,
November 9, 2025**

Time: 3:30 PM – 4:15 PM ET

Refreshments will be provided^b



**TLM Theater #2
Exhibit Hall D
Walter E. Washington
Convention Center
Washington, DC**

**Plan to arrive early to reserve your seat. Space is limited.
Attendance is limited to full-access attendees only.**

Program Description

Join us as we discuss the importance of early identification of MASH (metabolic dysfunction-associated steatohepatitis), including how to accurately identify and select patients who are at risk for clinically significant fibrosis. We will also discuss clinical trial data for patients with MASH and stage 2 or 3 fibrosis.

This program is sponsored by Novo Nordisk. The faculty will be compensated for their participation in this program. This is a promotional education presentation; it will not be certified for continuing medical education credit.

^aPresentation contains product-related education.

^bNovo Nordisk will report all transfers of value, including meals, as required by law. Please refrain from consuming any meals available at this event if you are a health care provider licensed in a state that prohibits, or applies limits to, such interactions. Please contact NNI Ethics & Compliance with any questions at NNIComplianceassist@NovoNordisk.com.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, Novo Nordisk will not provide alcohol at its programs, and attendance at this program is limited to health care professionals with an educational need to receive the information. Additionally, attendance by guests or spouses is not appropriate and cannot be accommodated.

The content of this Product Theater and opinions expressed by the presenters are those of the sponsor or presenters and not those of the American Association for the Study of Liver Diseases (AASLD).

Refreshments and the content of the Product Theater are the sole responsibility of Novo Nordisk Inc.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2025 Novo Nordisk

All rights reserved.

US25SN00727

September 2025



Sunday, Nov. 9

Advancing the Management of Cholestatic Liver Disease: Optimizing Treatment Pathways and Emerging Therapies

12:30 – 2:00 PM

Convention Center, Room 152

SUPPORTED BY: Ipsen Biopharmaceuticals, Inc.

ORGANIZED BY: PeerVoice

CME PROVIDER: USF Health

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Tara Kearns, MSW, LMSW; Kris V. Kowdley, MD; Nisreen Soufi, MD

In this activity, experts in adult and paediatric hepatology and gastroenterology explore practical strategies and evidence-based tools to diagnose and facilitate tailored treatment decision-making for primary biliary cholangitis (PBC) and progressive familial intrahepatic cholestasis (PFIC).

LEARNING OBJECTIVES

- Utilize practical approaches, including evidence-based tools, to evaluate and predict response to therapy and facilitate treatment decision-making in patients with cholestatic liver disease
- Appraise the data from trials and studies examining the safety and efficacy of therapies in PBC and PFIC
- Implement evidence-based treatment strategies to optimize clinical and patient-related outcomes in the management of PBC and PFIC
- Describe the clinical presentation and biochemical abnormalities in patients with PBC and PFIC

For more information and to register, visit: www.peervoice.com/Liver-DC25



YOUR FRONT-ROW SEAT TO LEADING LIVER SCIENCE

Join AASLD's Science in the Park sessions for a unique opportunity to connect with journal editors, thought leaders, and the broader hepatology community.

FRIDAY, NOV. 7

12:45 – 1:15 PM: HEPATOLOGY Cholestatic Special Issue

3:45 – 4:15 PM: Breakthrough Biomarkers in HBV

SATURDAY, NOV. 8

12:45 – 1:15 PM: How I Utilize Palliative Care

3:45 – 4:15 PM: Meet the New Liver Transplantation Editors & Pitch Your Article

SUNDAY, NOV. 9

12:45 – 1:15 PM: The Power of Multidisciplinary Care for ALD

3:45 – 4:15 PM: ILTS Portopulmonary Hypertension Guideline Update

MONDAY, NOV. 10

12:45 – 1:15 PM: HCC Immunotherapy as a Bridge to LT

3:45 – 4:15 PM: AASLD Practice Guideline on Treatment of Chronic Hepatitis B



Zydus Therapeutics is dedicated
to developing transformative
treatments for people living with
rare and serious diseases.

VISIT BOOTH # 651

zydustx.com



New Horizons in MASH Management

12:30 – 2:00 PM

Convention Center, Room 150

SUPPORTED BY: Inventiva

ORGANIZED BY: Medscape Education

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Manal Abdelmalek, MD, MPH, FAASLD; Rohit Loomba, MD, MHSc; Philip Newsome, MBChB, PhD, FRCPE, FMedSci

Join us for a symposium on metabolic dysfunction-associated steatohepatitis (MASH) designed to encourage the exchange of ideas between leaders in the field and attendees.

LEARNING OBJECTIVES

Upon completion of this activity, participants will have increased knowledge regarding the:

- Data for new and emerging treatments for MASH
- Mechanisms of action for emerging MASH therapies in relation to MASH pathophysiology
- Similarities and differences of endpoints for clinical trials for emerging MASH therapies

For more information and to register, visit: www.medscape.org/sympo/mash-management-adventures

Monday, Nov. 10

Beyond the Status Quo: Exploring the Future Impact of HBV Innovations

12:30 – 2:00 PM

Convention Center, Room 152

SUPPORTED BY: Aligos Therapeutics

ORGANIZED BY: Clinical Care Options, LLC

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Jordan J. Feld, MD, MPH; Mark Sulkowski, MD, FAASLD; Grace L. H. Wong, MD, MBChB (Hons), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine)

This engaging symposium will provide insights into recent innovations in the management of chronic hepatitis B. Expert faculty will discuss emerging biomarkers, investigational therapies aimed at chronic viral suppression and functional cure, and how these advances may help address existing gaps in care and improve long-term patient outcomes.

LEARNING OBJECTIVES

- Evaluate the limitations of current antiviral therapy for HBV
- Outline the role of emerging biomarkers in evaluating disease status and treatment response for patients with HBV
- Examine the role of emerging agents for chronic HBV suppression and their potential to improve patient outcomes

For more information and to register, visit: clinicaloptions.com/events/hbv-innovations/hbv-innovations/22094-36992

Connecting the Clues Lung and Liver Considerations in Diagnosing Alpha-1 Antitrypsin Deficiency

SATURDAY, NOVEMBER 8, 2025 | 1:00 PM – 2:00 PM ET

REGISTRATION AND LUNCH: 12:30 PM | PRESENTATION: 1:00 PM

WALTER E. WASHINGTON CONVENTION CENTER, 801 ALLEN Y. LEW PLACE NW
WASHINGTON, DC | **ROOM: ROOM 150**

HYBRID 

CHAIR



Aleksander Krag, MD, PhD, MBA
Professor
Director, Centre for Liver Research
(FLASH) Odense University Hospital
DIAS Chair of Health Sciences,
University of Southern Denmark
Odense, Denmark

PANELISTS



James K Stoller, MD, MS
Chief of Education, Cleveland Clinic
Jean Wall Bennett Chair
in Emphysema Research
Samson Global Leadership
Academy Chair
Professor of Medicine and Senior
Associate Dean, Cleveland Clinic
Lerner College of Medicine of Case
Western Reserve University
Cleveland, Ohio, United States



Pavel Strnad, MD
Professor
Department of Internal Medicine III
University Hospital Aachen
Aachen, Germany

AGENDA

1:00 PM

Welcome and Introduction

Aleksander Krag, MD, PhD, MBA;
Patient Video

1:05 PM

Working Together: Case Challenges in AATD-Associated Liver Disease

James K Stoller, MD, MS; Pavel Strnad, MD

1:40 PM

Panel Discussion: Shortening the Diagnostic Journey and Improving Outcomes for Patients With AATD

All Faculty

1:55 PM

Concluding Remark and Audience Q&A

Aleksander Krag, MD, PhD, MBA



Register Now!

For more information and to register, visit:

www.medscape.org/sympo/aatd2025

PRESENTED FOR ATTENDEES OF THE LIVER MEETING® 2025. THIS EVENT/FUNCTION IS PROVIDED BY MEDSCAPE
EDUCATION GLOBAL AND SUPPORTED BY TAKEDA. THIS IS NOT AN OFFICIAL EVENT/FUNCTION OF THE AMERICAN
ASSOCIATION FOR THE STUDY OF LIVER DISEASES.

Getting to Grips With Non-Invasive Tests to Assess Liver Fibrosis and Patient Eligibility for Novel MASH Therapies

12:30 – 2:00 PM

Convention Center, Room 150

SUPPORTED BY: Siemens Healthineers

ORGANIZED BY: Medscape Education

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Quentin Anstee, MBBS, PhD, FRCP; Meena B. Bansal, MD, FAASLD; Arun Sanyal, MD

Join us for a symposium on liver fibrosis designed to encourage the exchange of ideas between leaders in the field and attendees.

LEARNING OBJECTIVES

Upon completion of this activity, participants will have increased knowledge regarding:

- Cut-off values for use of noninvasive tests to assess liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)
- Clinical data on novel therapies for MASH
- Evaluating liver fibrosis in patients with MASH
- Assessment for liver fibrosis using noninvasive tests

For more information and to register, visit: <https://www.medscape.org/sympo/liver-fibrosis-noninvasive-test>

Zetomipzomib and the PORTOLA Trial: A Transformative Step Forward in Autoimmune Hepatitis (AIH)

Sunday, November 9th, 1:30 – 2:00 PM ET
Exhibit Hall D — Theater #2



Christopher J. Kirk, PhD
CEO, Kezar Life Sciences



Craig Lammert, MD
Associate Professor of Medicine,
Indiana University School of Medicine

Scan the QR code to learn more:



PORTOLA

KEZAR
LIFE SCIENCES



This program is sponsored by Kezar Life Sciences.

Zetomipzomib is an investigational product and has not been approved for commercial use in the United States or any country for any indication.



The Steatotic Liver Showdown

A Game Show on MASLD/MASH

FRIDAY, NOVEMBER 7, 2025 | 8:00 PM – 9:15 PM ET

REGISTRATION AND DINNER: 7:30 PM | PRESENTATION: 8:00 PM

MARRIOTT MARQUIS, 901 MASSACHUSETTS AVE NW
WASHINGTON, DC | **ROOM:** MARQUIS BALLROOM SALON 6

HYBRID

HOST



Alok Patel, MD
Assistant Professor of Pediatrics
Stanford Medicine Children's Health
Palo Alto, California

MODERATOR



Mazen Nouredin, MD, MHSc
Professor of Medicine
Department of Medicine
J.C. Walter Jr. Transplant Center
Houston Methodist Hospital
Director, Houston Research Institute
CSO and Co-Chair
of the Board Summit
and Pinnacle Clinical Research
Houston, Texas

PANELISTS



Meena B. Bansal, MD, FAASLD
Professor of Medicine
Chief, Division of Liver Diseases
Director, MASLD/MASH
Center of Excellence
Icahn School of Medicine
at Mount Sinai
New York, New York



Sonal Kumar, MD, MPH
Assistant Professor of Medicine
Director, General Gastroenterology
and Hepatology
Director
Innovative Center for Health
and Nutrition
in Gastroenterology (ICHANGE)
Weill Cornell Medicine
New York, New York

AGENDA

8:00 PM

Welcome and Introductions

8:05 PM

**Round 1: Metabolic dysfunction-associated
steatohepatitis (MASH) Risk Factors
and Implications for Progression**
Meena B. Bansal, MD, FAASLD

8:25 PM

**Round 2: Incretin-Based Therapies for MASH:
What Are the Data?**
Sonal Kumar, MD, MPH

8:50 PM

**Round 3: Applying MASH Guidelines
in Practice**
Mazen Nouredin, MD, MHSc

9:05 PM

Concluding Remarks and Q&A

9:15 PM

Adjourn



Register Now!

For more information and to register, visit:

www.medscape.org/sympo/liver-showdown

PRESENTED FOR ATTENDEES OF THE LIVER MEETING® 2025. THIS EVENT/FUNCTION IS PROVIDED BY
MEDSCAPE EDUCATION AND SUPPORTED BY INDUSTRY SUPPORTER(S). THIS IS NOT AN OFFICIAL
EVENT/FUNCTION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.

TLM THEATERS

Listings current as of October 10, 2025. Please refer to mobile app for updates.

Sunday, Nov. 9

Chronic Hepatitis B in Focus: Practical Strategies for Patient-Centered Care

10:00 - 10:45 AM

Convention Center, Exhibit Hall D/E, TLM Theater 1

SUPPORTED BY: GSK Medical

This disease state education theater will focus on chronic hepatitis B, covering the standard of care, patient care cascade, and clinical management considerations. Expert insights will be shared through engaging case studies and a dynamic panel discussion.

PRESENTERS: Mandana Khalili, MD; Paul Y. Kwo, MD; Norah Terrault, MD

Clinical Deep Dive: Unlocking the treatment potential of Rezdiffra

10:00 - 10:45 AM

Convention Center, Exhibit Hall D/E, TLM Theater 2

SUPPORTED BY: Madrigal

Please join us for an engaging and highly anticipated educational panel presentation focusing on a treatment option for patients with MASH, including the clinical data and patient cases.

PRESENTER: Sammy Saab, MD, MPH, AGAF, FAASLD, FACP; Lance Stein, MD

Getting to Grips With Noninvasive Tests to Assess Liver Fibrosis and Patient Eligibility for Novel MASH Therapies

MONDAY, NOVEMBER 10, 2025 | 12:30 PM – 2:00 PM ET

REGISTRATION AND LUNCH: 12:15 PM | PRESENTATION: 12:30 PM

WALTER E. WASHINGTON CONVENTION CENTER, 801 ALLEN Y. LEW PLACE NW
WASHINGTON, DC | **ROOM: ROOM 105**

HYBRID 

CHAIR



Arun Sanyal, MD
Professor of Medicine
Virginia Commonwealth University
School of Medicine
Richmond, Virginia

PANELISTS



Quentin Anstee, MBBS, PhD, FRCP
Professor of Experimental Hepatology
and Honorary Consultant Hepatologist
Translations and Clinical Research
Institute Faculty of Medical Sciences
Newcastle University
Newcastle Upon Tyne
United Kingdom



Meena B. Bansal, MD, FAASLD
Professor of Medicine
Chief, Division of Liver Diseases
Director, MASLD/MASH
Center of Excellence
Icahn School of Medicine
at Mount Sinai
New York, New York

AGENDA

12:30 PM
Introduction

12:35 PM
*Overview of the Pathophysiology
of metabolic dysfunction-associated
steatohepatitis (MASH) and the Rationale
for Novel Therapies*

12:45 PM
*Expert Insights on Current and Emerging
Therapies for MASH*

1:00 PM
*Current Approaches to Assessing Fibrosis
in MASH*

1:15 PM
*Understanding Cut-Off Values
in Implementing noninvasive tests (NITs)
for Identification of Patients for Novel
Therapies: Data Deep Dive*

1:30 PM
*Evolution of Use of NITs to Assess Fibrosis
in MASH*

1:40 PM
Audience Q&A

1:55 PM
Summary and Conclusions



Register Now!

For more information and to register, visit:

www.medscape.org/sympo/liver-fibrosis-noninvasive-test

PRESENTED FOR ATTENDEES OF THE LIVER MEETING® 2025. THIS EVENT/FUNCTION IS PROVIDED
BY MEDSCAPE EDUCATION AND SUPPORTED BY SIEMENS HEALTHINEERS.

THIS IS NOT AN OFFICIAL EVENT/FUNCTION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.

Supported by an independent educational grant from Siemens Healthineers.

Produced by Medscape **LIVE!**

Comprehensive CHB Testing: Quantitative & Qualitative HBsAg and Beyond**12:30 - 1:00 PM***Convention Center, Exhibit Hall D/E, TLM Theater 1***SUPPORTED BY:** GSK

This session will explore the clinical significance of comprehensive biomarker testing in chronic hepatitis B (CHB), focusing on how quantitative and qualitative HBsAg, HBeAg, and HBV DNA testing can help offer more personalized care to CHB patients by characterizing disease phases, supporting better-informed treatment decisions, and improving monitoring strategies.

PRESENTERS: Calvin Q. Pan, MD, MACP, FAASLD

Summary of TERLIVAZ® (terlipressin): the first FDA-approved treatment for HRS in adults with rapid reduction in kidney function**12:30 - 1:00 PM***Convention Center, Exhibit Hall D/E, TLM Theater 2***SUPPORTED BY:** Mallinckrodt Pharmaceuticals

The Summary of TERLIVAZ® (terlipressin): the first FDA-approved treatment for HRS in adults with rapid reduction in kidney function. This TLM theater will highlight the importance of early recognition and current diagnosis and treatment recommendations for hepatorenal syndrome-acute kidney injury (HRS-AKI).

PRESENTER: Lance L. Stein MD, FAASLD, AGAF, FACP

Could Your Patients With Unexplained Cholestasis Have Progressive Familial Intrahepatic Cholestasis (PFIC)? When to Suspect and Considerations for Treatment**1:30 - 2:00 PM***Convention Center, Exhibit Hall D/E, TLM Theater 1***SUPPORTED BY:** Mirum Pharmaceuticals

Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders associated with the accumulation of toxic bile acids and progressive liver injury. In this presentation, Dr. Gish will review the signs and symptoms of PFIC, examine the role of genetic testing in diagnosis, and discuss considerations for treatment of adults with PFIC.

PRESENTERS: Robert Gish, MD

New Horizons in MASH Management

SUNDAY, NOVEMBER 9, 2025 | 12:30 PM – 2:00 PM ET

REGISTRATION AND LUNCH: 12:15 PM | PRESENTATION: 12:30 PM

WALTER E. WASHINGTON CONVENTION CENTER, 801 ALLEN Y. LEW PLACE NW
WASHINGTON, DC | **ROOM: ROOM 150**

HYBRID 

CHAIR



Rohit Loomba, MD, MHSc
Professor of Medicine
Chief, Division of Gastroenterology
and Hepatology
Director, UCSD MASLD
Research Center
UC San Diego Health
San Diego, California, United States

PANELISTS



Philip Newsome, MBChB, PhD, FRCPE, FMedSci
Professor of Hepatology
King's College London
Director of Roger Williams Institute
of Liver Studies
& Hon Consultant Hepatologist
King's College Hospital
Director of King's Health Partners
Centre for Translational Medicine
King's College
London, England



Manal F. Abdelmalek, MD, MPH, FAASLD
Professor of Medicine
Director,
MASLD Clinical Research Program
Mayo Clinic
Rochester, Minnesota, United States

AGENDA

12:15 PM

Registration and Lunch

12:30 PM

Welcome and Introductions

12:35 PM

Pathophysiology of MASLD and MASH

Rohit Loomba, MD, MHSc

12:50 PM

Emerging Therapies for MASH

• *Incretin-Based Therapies*

Philip Newsome, MBChB, PhD,
FRCPE, FMedSci

• *PPAR Agonists*

Manal F. Abdelmalek, MD, MPH

• *FGF-21 Analogs*

Rohit Loomba, MD, MHSc

• *THR-β Agonists*

Manal F. Abdelmalek, MD, MPH

1:45 PM

Concluding Remarks and Q&A

Rohit Loomba, MD, MHSc

2:00 PM

Adjourn



Register Now!

For more information and to register, visit:

www.medscape.org/sympo/mash-management-adventures

PRESENTED FOR ATTENDEES OF THE LIVER MEETING® 2025. THIS EVENT/FUNCTION IS PROVIDED BY MEDSCAPE EDUCATION AND SUPPORTED BY INDUSTRY SUPPORTER(S). THIS IS NOT AN OFFICIAL EVENT/FUNCTION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.

Zetomipzomib and the PORTOLA Trial: A Transformative Step Forward in Autoimmune Hepatitis (AIH)**1:30 - 2:00 PM***Convention Center, Exhibit Hall D/E, TLM Theater 2***SUPPORTED BY:** Kezar Life Sciences, Inc

This session will present findings from the Phase 2a PORTOLA trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in autoimmune hepatitis. Attendees will hear insights on the study design and clinical outcomes, followed by expert discussion on the potential role of immunoproteasome inhibition in advancing treatment for this challenging disease.

PRESENTERS: Christopher J. Kirk, PhD; Craig Lammert, MD, MS**Advances in MASH: Data From a Phase 3 Study****3:30 - 4:15 PM***Convention Center, Exhibit Hall D/E, TLM Theater 2***SUPPORTED BY:** Novo Nordisk, Inc.

Join us as we discuss the importance of early identification of MASH (metabolic dysfunction-associated steatohepatitis), including how to accurately identify and select patients who are at risk for clinically significant fibrosis. We will also discuss clinical trial data for patients with MASH and stage 2 or 3 fibrosis.

PRESENTERS: Manal F. Abdelmalek, MD, MPH, FAASLD**Evolving Approach to Second-Line Treatment in PBC: A Case-Based Discussion****3:30 - 4:15 PM***Convention Center, Exhibit Hall D/E, TLM Theater 1***SUPPORTED BY:** Ipsen

This session will highlight evolving approaches to second-line treatment in primary biliary cholangitis (PBC) through a case-based discussion. It will provide practical insights and foster a dynamic exchange between leading hepatologists.

PRESENTERS: Sonal Kumar, MD; David W. Victor, MD**What Does TLM Mean to You?**

Scan the QR code to share what you love most about #TLM. Don't forget to stop by both AASLD Hubs located on L-Street Bridge and in the exhibit hall booth #916.





The Capitol Challenge

Mastering PBC Care

FRIDAY, NOVEMBER 7, 2025 | 12:45 PM – 2:00 PM ET

REGISTRATION AND LUNCH: 12:30 PM | PRESENTATION: 12:45 PM

WALTER E. WASHINGTON CONVENTION CENTER, 801 ALLEN Y. LEW PLACE NW
WASHINGTON, DC | **ROOM: ROOM 150**

HYBRID

MODERATOR



Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Professor of Medicine
Elson S. Floyd College of Medicine
Washington State University
Director, Liver Institute Northwest
Seattle, Washington, United States

PANELISTS



Steven L. Flamm, MD, FAASLD, FACP
Professor of Medicine
Department of Internal Medicine
Division of Digestive Diseases
and Nutrition
Director of Research
Department of Hepatology
Rush University Medical Center
Chicago, Illinois, United States



Emma Culver, MBChB, DPhil, FRCP
Honorary Senior Lecturer
Consultant Hepatologist
John Radcliffe Hospital
University of Oxford
Oxford, United Kingdom

AGENDA

12:30 PM

Lunch and Registration

12:45 PM

Welcome and Introductions

12:50 PM

Lap 1: Smithsonian Institute – Exploring primary biliary cholangitis (PBC) Diagnosis and Risk Assessment

Emma Culver, MBChB, DPhil, FRCP

1:10 PM

Lap 2: Lincoln Memorial – Paradigms in Personalized PBC Care

Steven L. Flamm, MD, FAASLD, FACP

1:30 PM

Lap 3: Washington Monument – Best Practices in PBC Disease Monitoring

Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG

1:50 PM

Concluding Remarks and Audience Q&A
All Faculty



Register Now!

For more information and to register, visit:

www.medscape.org/sympo/pbc-challenge-25

PRESENTED FOR ATTENDEES OF THE LIVER MEETING® 2025. THIS EVENT/FUNCTION IS PROVIDED BY MEDSCAPE EDUCATION AND SUPPORTED BY INTERCEPT PHARMACEUTICALS, INC. THIS IS NOT AN OFFICIAL EVENT/FUNCTION OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.

Monday, Nov. 10

Discover a Treatment Option for Pruritus in Patients With Alagille Syndrome or PFIC

10:00 - 10:45 AM

Convention Center, Exhibit Hall D/E, TLM Theater 1

SUPPORTED BY: Ipsen Biopharmaceuticals

Learn more about a treatment option for your patients with progressive familial intrahepatic cholestasis (PFIC) or Alagille syndrome (ALGS). Join us as Dr. Sheflin-Findling discusses an overview of PFIC and ALGS and a deep-dive into an approved treatment option for your pediatric, adolescent, and adult patients.

PRESENTERS: Shari Sheflin, DO

Clinical Deep Dive: Unlocking the treatment potential of Rezdiffra

10:00 - 10:45 AM

Convention Center, Exhibit Hall D/E, TLM Theater 2

SUPPORTED BY: Madrigal

Please join us for an engaging and highly anticipated educational panel presentation focusing on a treatment option for patients with MASH, including the clinical data and patient cases.

PRESENTERS: Steven Flamm, MD, FAASLD, FACG; Gia Landry, MD, MPH

Biliary Atresia: How Do We Better Understand Pathways and Disease Progression?

12:30 - 1:00 PM

Convention Center, Exhibit Hall D/E, TLM Theater 1

SUPPORTED BY: Ipsen Biopharmaceuticals

The Ipsen-sponsored TLM Theatre will explore current approaches to the management of Biliary Atresia, highlighting opportunities for further optimization of care and patient outcomes. Prognostic biomarkers and the underlying pathophysiology driving disease progression in Biliary Atresia will also be addressed.

PRESENTERS: Binita Kamath, MBBChir, FAASLD; Ronald J. Sokol, MD, FAASLD



**To Learn More
Stop by Booth #839**



Committed to Innovation – Advancing Therapies for the Treatment of HCV and Other Viral Diseases

Atea is advancing the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, in the first global Phase 3 head-to-head program of direct-acting antivirals for the treatment of hepatitis C virus (HCV) infection. In a global Phase 2 eight-week treatment study (N=275), the regimen met its primary endpoints, achieving a 98% sustained virologic response at 12 weeks after treatment (SVR12)* and was generally well-tolerated (NCT05904470).

The incidence of HCV remains a significant public health burden, with up to 4 million people in the US infected.

Leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry, and virology, Atea is dedicated to advancing oral antiviral therapeutics for patients worldwide affected by serious viral diseases.

Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel, oral antiviral treatments.

*Per-protocol treatment adherent population

Find out more at www.ateapharma.com



Copyright © 2025 By Atea Pharmaceuticals
All rights reserved

Atea Pharmaceuticals, Inc.
225 Franklin Street
Suite 2100
Boston, MA 02110
+1 (857) 284-8891

ADVANCING Treatment in Primary Biliary Cholangitis (PBC): Insights Into a Selective PPAR δ Agonist

3:30 – 4:15 PM

Convention Center, Exhibit Hall D/E, TLM Theater 1

SUPPORTED BY: Gilead Sciences

Join us for a product theater on an FDA-approved treatment option for primary biliary cholangitis (PBC). Gain insights into how this therapy may support improved PBC outcomes for the appropriate patients affected by this chronic liver disease.

PRESENTERS: John M. Vierling, MD, FACP, FAASLD, AGAF

More Than Fat in the Liver: The Metabolic Burden of Excess Adiposity

3:30 – 4:15 PM

Convention Center, Exhibit Hall D/E, TLM Theater 2

SUPPORTED BY: Boehringer Ingelheim Pharmaceuticals, Inc.


Explore the metabolic connections between obesity, MASLD/MASH, and cardiometabolic diseases, and how incorporating obesity care in hepatology practice can improve multiple health outcomes. Join expert clinicians for an in-depth discussion on the vital role of hepatology in obesity care and the importance of collaborative care.

PRESENTERS: Angela Fitch, MD, FACP, FOMA, Dipl. ABOM; Nadege Gunn, MD, CPI, DABOM, FAASLD

Collaborate in The Park @ TLM

The Park @ TLM is your relaxation center located in the heart of the Exhibit Hall.

- Join a friendly game of **chess** — strategy, fun, and camaraderie all in one move!
- FORE! Test your skills in the **golf simulator** while connecting with fellow attendees between sessions.
- Cheer on fellow attendees during the annual **TLM Pickleball Tournament**.



DINNER
PROVIDED

MASLD AND CARDIOMETABOLIC SYNDROME:

THE DREAM MDT TEAM!

8TH NOV. 2025/7.30-9.30 PM
MARRIOTT MARQUIS HOTEL
MARQUIS BALLROOM SALON 6

SPEAKERS



**CHAIRIED BY
DR LEE M.
KAPLAN**
Director of Obesity
Metabolism & Nutrition
Institute and Weight
Center, Massachusetts



**DR KATHY E.
MAGLIATO**
Cardiothoracic
Surgeon and
Entrepreneur,
Los Angeles



**DR JACQUELINE
O'LEARY**
Transplant
Hepatologist and
Public Health, Dallas



**DR JOSE
VARGAS**
Preventative Cardiology,
Cardiology Imaging,
Cardiovascular genetics,
Washington DC



**DR NIHARIKA R.
SAMALA**
Assistant Prof
Hepatology,
Indiana



**TO REGISTER USE
THE LINK OR SCAN
THE QR-CODE**
[healthpromatch.com/
courseRegistration/
?courseId=6](https://healthpromatch.com/courseRegistration/?courseId=6)



1,5 CME
POINTS

Presented for attendees of The Liver Meeting® 2025. This event/function is provided by HealthProMatch and supported by Perspectrum Ltd. This is not an official event/function of the American Association for the Study of Liver Diseases.

EVERY PATIENT DESERVES A BETTER JOURNEY

From diagnosis to end-of-life care, **your role is vital** – AASLD's courses are here to support you through every step.



AASLD's **Liver Cancer 100 Series** grounds you in risk factors, screening, and staging. Built on our HCC guidance, this series shows how ultrasounds with AFP improve early detection and survival.



With AASLD's **e-learning activities**, turn new findings and multidisciplinary approaches into practice for better patient outcomes.



AASLD's **Palliative Care and Advanced Liver Disease Course**, shaped by our 2022 guidance, helps you deliver early, evidence-based palliative care that eases burdens and preserves the dignity of patients suffering from decompensated cirrhosis.



**EXPLORE
OUR COURSES**



AASLD
EDUCATION

Rezdiffra™

resmetirom tablets

60mg • 80mg • 100mg



Discover what this treatment may offer



Visit Booth #720

Learn more at RezdiffraHCP.com



Madrigal

© 2025 Madrigal Pharmaceuticals, Inc. All rights reserved.
Rezdiffra™ and its related logo are trademarks of Madrigal Pharmaceuticals, Inc.
US-PP-RES-01008-v2 09/25